FIELD: chemistry.
SUBSTANCE: invention relates to tetrahydrochinoline derivatives represented by general formula , where t is equal 0, 1 or 2; each R independently represents H, alkyl, alkenyl or cycloalkyl; n is equal 0; R is selected from group, consisting of H, alkyl, halogenalkyl, cycloalkyl, alkenyl, alkinyl, -RaAy, -RaOR5 or group - Racycloalkyl, and where R2 is not substituted with amine or alkylamine; each R4 independently represents halogen; m is equal 0, 1 or 2; each R5 independently represents H, alkyl, alkenyl, alkinyl, cycloalkyl; p is equal 0 or 1; y represents -NR10-, -O-, -S-; X represents -N(R10)2, -RaN(R10)2, -AyN(R10)2, -RaAyN(R10)2, -AyRaN(R10)2, -RaAyRaN(R10)2, -Het, -RaHet, -HetN(R10)2, -RaHetN(R10)2, -HetRaN(R10)2, -RaHetRaN(R10)2, -HetRaAy or -HetRaHet; each Ra independently represents alkylene, possibly suibstituted with one or more than one alkyl or hydroxyl, cycloalkylene, possibly substituted with one or more than one alkyl or hydroxyl; each R10 independently represents H, alkyl, cycloalkyl, alkenyl, alkinyl, cycloalkenyl or -Ra-cycloalkyl; each Ay independently represents possibly substituted phenyl or naphtyl group; each Het independently represents possibly substituted 3-12-member mono- or polycyclic heterocyclyl group, containing as heteroatoms N, or 5-7-member possibly substituted heteroaryl group, containing as heteroatom N; or its pharmaceutically acceptable salts or ethers. Also described are methods of obtaining compounds of formula (I-G).
EFFECT: obtained are novel compounds, which demonstrate protective against HIV-infection effect on target-cells by means of specific binding with chemokine receptor and which influence binding of natural ligand or chemokine with target-cell receptor, such as CXCR4 and/or CCR5.
54 cl, 2 tbl, 90 ex
Title | Year | Author | Number |
---|---|---|---|
TETRAHYDROQUINOLINE DERIVATIVES AND BASED PHARMACEUTICAL COMPOSITION FOR HIV INFECTION TREATMENT AND PREVENTION | 2005 |
|
RU2351592C2 |
DERIVATIVES OF TETRAHYDROQUINOLINE SHOWING PROTECTIVE ACTION FROM HIV-INFECTION | 2005 |
|
RU2350604C2 |
PREPARATION COMPRISING INHIBITOR OF HETEROTRIMERIC G PROTEINS SIGNAL TRANSDUCTION IN COMBINATION WITH OTHER CYTOSTATIC AGENT FOR THERAPEUTIC USING IN CANCER TREATMENT | 2000 |
|
RU2298417C2 |
CERTAIN PROTEIN KINASE INHIBITORS | 2015 |
|
RU2671494C2 |
HIV-INHIBITING 5-(HYDROXYMETHYLENE- AND AMINOMETHYLENE)SUBSTITUTED PYRIMIDINES | 2007 |
|
RU2452737C2 |
2-ARYLIMIDAZO[1,2-b]PYRIDAZINE,2-PHENYLIMIDAZO[1,2-a]PYRIDINE AND 2-PHENYLIMIDAZO[1,2-a]PYRAZINE DERIVATIVES | 2011 |
|
RU2598385C2 |
ANELLATED CABAMOYLAZAHETEROCYCLES, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARING | 2005 |
|
RU2281947C1 |
IMIDAZO[1, 2-a]PYRIDINE COMPOUNDS AS INHIBITORS OF RECEPTOR TYROSINKINASES | 2008 |
|
RU2467008C2 |
METHODS FOR PRODUCTION OF RACEMIC AMINOSUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE OR RACEMIC AMINOSUBSTITUTED 5,6,7,8-TETRAHYDROISOQUINOLINE, METHODS FOR SEPARATION AND RACEMIZATION THEREOF, METHODS FOR PRODUCTION OF KETOSUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE OR KETOSUBSTITUTED 5,6,7,8-TETRAHYDROISOQUINOLINE, METHOD FOR PRODUCTION OF ENANTIOMER PF CONDENSED BYCYCLIC RING SUBSTITUTED WITH PRIMARY AMINE, 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES | 2002 |
|
RU2308451C2 |
AZAINDOL DERIVATIVES AS FACTOR Xa INHIBITORS | 2004 |
|
RU2330853C2 |
Authors
Dates
2009-04-20—Published
2005-08-31—Filed